Health Canada Report: No OTC NSAID Label Changes Needed
This article was originally published in The Tan Sheet
Executive Summary
Canadian manufacturers of nonprescription ibuprofen products will not have to make any label changes regarding cardiovascular risks that may be associated with the non-steroidal anti-inflammatory drugs class, Health Canada states in documents released June 14
You may also be interested in...
NSAID Labeling Revisions Revised By FDA; Compliance Date Extended
FDA has deleted the part of its recommended heart risk warning for NSAIDs that discourages use for "longer than 10 days or more than the recommended dose.
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement